共 50 条
Identification and validation of human DNA ligase inhibitors using computer-aided drug design
被引:60
|作者:
Zhong, Shijun
[1
]
Chen, Xi
[2
]
Zhu, Xiao
[1
]
Dziegielewska, Barbara
[2
]
Bachman, Kurtis E.
[3
]
Ellenberger, Tom
[4
]
Ballin, Jeff D.
[5
]
Wilson, Gerald M.
[5
]
Tomkinson, Alan E.
[2
,3
]
MacKerell, Alexander D., Jr.
[1
]
机构:
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[4] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA
[5] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
关键词:
D O I:
10.1021/jm8001668
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Linking together of DNA strands by DNA ligases is essential for DNA replication and repair. Since many therapies used to treat cancer act by causing DNA damage, there is growing interest in the development of DNA repair inhibitors. Accordingly, virtual database screening and experimental evaluation were applied to identify inhibitors of human DNA ligase I (hLigI). When a DNA binding site within the DNA binding domain (DBD) of hLigI was targeted, more than I million compounds were screened from which 192 were chosen for experimental evaluation. In DNA joining assays, 10 compounds specifically inhibited hLigI, 5 of which also inhibited the proliferation of cultured human cell lines. Analysis of the 10 active compounds revealed the utility of including multiple protein conformations and chemical clustering in the virtual screening procedure. The identified ligase inhibitors are structurally diverse and have druglike physical and molecular characteristics making them ideal for further drug development studies.
引用
收藏
页码:4553 / 4562
页数:10
相关论文